A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects of Food in Single/Multiple Oral Administration of DA-302168S Tablets
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Obesity therapies (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Chengdu DIAO Pharmaceutical Group
Most Recent Events
- 15 Apr 2025 Status changed from recruiting to completed.
- 08 Aug 2024 New trial record